Neuroscience Antibody Assays Market: Qualitative Analysis, Quantitative Analysis, Forecast up to 2030

SDKI Inc. published a new report on the neuroscience antibody assay market. This study includes the statistical and analytical approaches needed to grow the neuroscience antibody assay market. The key industry insights provided in the report provide readers with better ideas about market overviews regarding existing market scenarios. In addition, the report contains a detailed discussion of current and future market trends related to market growth.

Report sample URL
https://www.sdki.jp/sample-request-109771

The global neuroscience antibody assay market is estimated to reach US $ 4.18 billion by 2023 from US $ 2.57 billion in 2018 and is expected to grow at a CAGR of 10.2%. Growth in this market is driven by rising rates of neurological disease, increased investment in neuroscience research, and growth in the pharmaceutical and biotechnology industries.

However, quality and cost concerns about antibody production are the main drivers of growth in this market.

Market Segments

Neuroscience antibody / assay markets are by product (consumables and equipment), technology (immunoassay (Elisa), molecular diagnostics), application (IVD), end-user (pharmaceutical and biotechnology companies, academia and research). Institutions, hospitals and diagnostic centers) and by region. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.

Report sample URL
https://www.sdki.jp/sample-request-109771

The consumables segment is expected to grow at a maximum CAGR during the forecast period.

Based on the product, the neuroscience antibody / assay market is divided into consumables and equipment. The consumables segment is expected to register the largest CAGR during the forecast period. Consistent use and frequent purchases of consumables, as well as rising government initiative in the genomics and proteomics research sector, are key factors supporting the growth of this segment.

The pharmaceutical and biotechnology enterprise segments are expected to dominate the market during the forecast period.

Based on the end user, the neuroscience antibody assay market is divided into pharmaceutical and biotechnology companies, academic and research institutes, hospitals and diagnostic centers. The pharmaceutical and biotechnology enterprise segment had the largest market share in 2018. The large share of this segment may be due to the high uptake of neuroscientific antibodies in the drug discovery and development process and the growing government initiative in the genomics and proteomics research sector.

Regional Overview

In 2018, North America has the largest market share, followed by Europe. Meanwhile, Asia plans to register the largest CAGR during the forecast period. The high growth in the Asian region is due to factors such as growing research on proteomics and genomics, favorable funding scenarios, and an increased incidence of neurological disorders in the region.

These regional segments are North America (US and Canada); Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, and other Asia Pacific); Latin America (Brazil, Mexico, Argentina, and other Latin). USA); Middle East and Africa (Israel, GCC [Saudi Arabia, Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, and other Middle East and Africa) and Europe (UK, Germany, France, Italy, Spain) , Hungary, Belgium, Netherlands, Luxemburg, NORDIC, Poland, Turkey, Russia and other Europe) and more.

Details of the survey report
https://www.sdki.jp/reports/neuroscience-antibodies-assays-market/109771

Key Players:

On the neuroscience antibody assay market are:
Thermo Fisher Scientific (USA)
Abcam (UK)
Bio-Rad (USA)
Merck KGaA (Germany)
BioLegend (USA)
Cell Signaling Technology (USA)
F. Hoffmann-La Roche (Switzerland)
GenScript (China)
Rockland Immunochemicals (USA)
Santa Cruz Biotechnology (USA)
Siemens (Germany)
Tecan ()
The study includes in-depth competitive analysis, corporate profiles, recent developments, and key market strategies for these leading companies in the neuroscience antibody assay market.

Contact Us

Hina Miyazu
15/F Cerulean Tower, 26-1 Sakuragaoka-cho
Tokyo, Shibuya-ku, Japan
+ 81345720790
sales@sdki.jp

SDKI Inc. Company Profile

SDKI Inc.'s goal is market scenarios in various countries such as Japan, China, the United States, Canada, the United Kingdom, and Germany. Is to clarify. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.

This release was published on openPR.